NCT04222842View on ClinicalTrials.gov

CM082 in Patients With Myopic Choroidal Neovascularization (CNV)

PHASE1SuspendedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

Myopic Choroidal Neovascularisation

Interventions

DRUG

CM082

Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing